The xCures technology platform uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.
Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The platform then provides these patients a personalized list of top treatment options and information about how to access them.
The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies.
The RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. The platform accepts records from any US-based institution, in any form, and compiles the data into a pan-cancer registry under an IRB-approved master protocol suitable for FDA submissions and medical publications.
xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options, and optimize options selection for future patients.
Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The platform then provides these patients a personalized list of top treatment options and information about how to access them.
The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies.
The RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. The platform accepts records from any US-based institution, in any form, and compiles the data into a pan-cancer registry under an IRB-approved master protocol suitable for FDA submissions and medical publications.
xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options, and optimize options selection for future patients.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $12.7M
Founded date: 2018
Investors 5
Date | Name | Website |
- | Vanedge Ca... | vanedgecap... |
- | HealthTech... | healthtech... |
- | Wavemaker ... | wavemaker3... |
11.01.2022 | Civilizati... | civilizati... |
- | Unbridled ... | unbridled.... |
Funding Rounds 1
Date | Series | Amount | Investors |
23.06.2021 | Series A | $12.7M | - |
Mentions in press and media 27
Date | Title | Description |
22.10.2024 | xCures Unveils Next-Generation AI-Powered Data Platform at HLTH Conference | The platform leverages AI to deliver real-time insights that will significantly reduce the time and effort needed to make informed clinical decisions. xCures, a pioneer in AI-driven healthcare data solutions, announced today its latest inno... |
16.09.2024 | Leveraging AI and Automation to Streamline Chart Reviews, Identify Treatment Options, and Prove Service Value, Upcoming Webinar Hosted by Xtalks | www.xcures.com In this free webinar, learn how AI can be applied to streamline clinical care, improve treatment outcomes and prove the value of healthcare services to stakeholders. Attendees will learn how to solve the missing medical recor... |
03.07.2024 | Expanded Access Program for gallium maltolate (GaM) Now Open | Investigational cancer treatment with the potential to slow brain tumor growth is now available for patients with relapsed/refractory glioblastoma. The opening of this EAP marks a significant milestone in our mission to combat glioblastoma”... |
28.05.2024 | Kidney Cancer Association enters strategic partnership with xCures | The partnership will empower patients with greater control over their health data and accelerate the discovery and approval of new treatments for kidney cancer. This partnership represents a significant step forward in leveraging real-world... |
24.05.2024 | xCures to showcase the value of its healthcare data platform at the 2024 ASCO Annual Meeting | xCures' patient-centric platform enables outcomes monitoring and evidence generation, providing insights into the best treatments, including for rare cancers. xCures has done what no one else has been able to do for rare diseases” — Paul Ke... |
01.02.2024 | xCures Expands AI Health Data Platform: Now Supporting All Therapeutic Areas and is Available as SaaS | The company’s platform expansion transforms the value of US healthcare data by harnessing real-time, regulatory-grade data in any therapeutic area to efficiently understand the complex medical histories of patients and drive research throug... |
06.12.2023 | xCures to offer clinical data extraction as a service in AWS Marketplace | AWS cloud configurations help xCures customers leverage the company’s data gathering and structuring services while maintaining secure private ownership of data Our clients can be confident that their data remains shielded by the finest dig... |
06.06.2023 | CureMatch and xCures Partner to Revolutionize the Standard for Precision Cancer Treatment Processes | CureMatch will leverage xCures technology that automatically creates a comprehensive outline of a patient’s medical history to improve treatment recommendations We are confident that we can accelerate the adoption of precision oncology and ... |
26.05.2023 | xCures showcases the Power of its Real-time Clinical data platform at ASCO Annual Meeting 2023 | Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations. Access to real-time, longitudinal, uninterrupted clinical data offers an unparalleled ca... |
20.12.2022 | xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study | RenovoRx's Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. Our therapy platform is challenging the standard-of-care treatment available to local... |
Show more